Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149102 | 0.87 | ALOX5 (0.44) | NPC1RAB9A | |
| SCHEMBL4128788 | 0.86 | HRH3 (0.49) | L3MBTL3L3MBTL1FAAHNPC1RAB9A | |
| SCHEMBL4133418 | 0.85 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1FAAHMCHR1 | |
| SCHEMBL4140118 | 0.84 | TDP2 (0.45) | L3MBTL3L3MBTL1FAAHHRH3 | |
| SCHEMBL4140115 | 0.84 | TDP2 (0.45) | L3MBTL3L3MBTL1FAAHHRH3 | |
| SCHEMBL4144270 | 0.84 | TDP2 (0.45) | L3MBTL3L3MBTL1FAAHHRH3 | |
| SCHEMBL4136371 | 0.83 | HRH3 (0.52) | L3MBTL3L3MBTL1HRH3MCHR1 | |
| SCHEMBL4136377 | 0.83 | HRH3 (0.52) | L3MBTL3L3MBTL1HRH3MCHR1 | |
| SCHEMBL4136321 | 0.81 | TDP2 (0.45) | L3MBTL3L3MBTL1FAAHHRH3 | |
| SCHEMBL4136188 | 0.80 | MAPK14 (0.50) | USP30L3MBTL1NPC1RAB9AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | disclosed |
| EP-2007749-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | Pfizer Products Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007105053-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | USP30 3191/4885CRBN 4746/4885L3MBTL3 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.